Journal of Vaccine Research 2024, Vol.14, No.2, 85-94 http://medscipublisher.com/index.php/jvr 93 Nadeem A., Shehzad A., Islam S., Al-Suhaimi E., and Lee Y., 2022, Mosquirix™ RTS, S/AS01 vaccine development, immunogenicity, and efficacy, Vaccines, 10(5): 713. https://doi.org/10.3390/vaccines10050713 PMid:35632469 PMCid:PMC9143879 Ng'ang'a P., Aduogo P., and Mutero C., 2021, Strengthening community and stakeholder participation in the implementation of integrated vector management for malaria control in western Kenya: a case study, Malaria Journal, 20: 1-14. https://doi.org/10.1186/s12936-021-03692-4 PMid:33740983 PMCid:PMC7977174 Nikolaeva D., Draper S., and Biswas S., 2015, Toward the development of effective transmission-blocking vaccines for malaria, Expert Review of Vaccines, 14: 653-680. https://doi.org/10.1586/14760584.2015.993383 PMid:25597923 Ogeto T., Ndubi F., Murithi M., Kagia R., Wambugu E., Suge T., Chepkirui C., Tonui J., Maiyo F., Momanyi L., and Walekhwa M., 2020, Malaria vaccines targeting the pre-erythrocytic stage: a scoping review, F1000Research, 9: 680. https://doi.org/10.12688/f1000research.24320.1 Olotu A., Urbano V., Hamad A., Eka M., Chemba M., Nyakarungu E., Raso J., Eburi E., Mandumbi D., Hergott D., Maas C., Ayekaba M., Milang D., Rivas M., Schindler T., Embon O., Ruben A., Saverino E., Abebe Y., Kc N., James E., Murshedkar T., Manoj A., Chakravarty S., Li M., Adams M., Schwabe C., Segura J., Daubenberger C., Tanner M., Tanner M., Richie T., Billingsley P., Sim B., Abdulla S., and Hoffman S., 2017, Advancing global health through development and clinical trials partnerships: a randomized, placebo-controlled, double-blind assessment of safety, tolerability, and immunogenicity of pfspz vaccine for malaria in healthy equatoguinean men, The American Journal of Tropical Medicine and Hygiene, 98: 308-318. https://doi.org/10.4269/ajtmh.17-0449 PMid:29141739 PMCid:PMC5928718 Pluess B., Tanser F., Lengeler C., and Sharp B., 2010, Indoor residual spraying for preventing malaria, The Cochrane database of systematic reviews, 4: CD006657. https://doi.org/10.1002/14651858.CD006657.pub2 PMid:20393950 PMCid:PMC6532743 Protopopoff N., Wright A., West P., Tigererwa R., Mosha F., Kisinza W., Kleinschmidt I., and Rowland M., 2015, Combination of insecticide treated nets and indoor residual spraying in northern Tanzania provides additional reduction in vector population density and malaria transmission rates compared to insecticide treated nets alone: a randomised control trial, PLoS ONE, 10(11): e0142671. https://doi.org/10.1371/journal.pone.0142671 PMid:26569492 PMCid:PMC4646432 Pryce J., Medley N., and Choi L., 2022, Indoor residual spraying for preventing malaria in communities using insecticide‐treated nets, The Cochrane Database of Systematic Reviews, (1). https://doi.org/10.1002/14651858.CD012688.pub3 PMid:35038163 PMCid:PMC8763033 Raghavendra K., Barik T., Reddy B., Sharma P., and Dash A., 2011, Malaria vector control: from past to future, Parasitology Research, 108: 757-779. https://doi.org/10.1007/s00436-010-2232-0 PMid:21229263 Regules J., Cicatelli S., Bennett J., Paolino K., Twomey P., Moon J., Kathcart A., Hauns K., Komisar J., Qabar A., Davidson S., Dutta S., Griffith M., Magee C., Wojnarski M., Livezey J., Kress A., Waterman P., Jongert E., Wille-Reece U., Volkmuth W., Emerling D., Robinson W., Lievens M., Morelle D., Lee C., Yassin-Rajkumar B., Weltzin R., Cohen J., Paris R., Waters N., Birkett A., Kaslow D., Ballou W., Ockenhouse C., and Vekemans J., 2016, Fractional third and fourth dose of RTS,S/AS01 malaria candidate vaccine: a phase 2a controlled human malaria parasite infection and immunogenicity study, The Journal of infectious diseases, 214(5): 762-771. https://doi.org/10.1093/infdis/jiw237 PMid:27296848 Seidlein L., Hanboonkunupakarn B., Jittamala P., Pongsuwan P., Chotivanich K., Tarning J., Hoglund R., Winterberg M., Mukaka M., Peerawaranun P., Sirithiranont P., Doran Z., Ockenhouse C., Ivinson K., Lee C., Birkett A., Kaslow D., Singhasivanon P., Day N., Dondorp A., White N., and Pukrittayakamee S., 2019, Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers, Human Vaccines & Immunotherapeutics, 16: 33-41. https://doi.org/10.1080/21645515.2019.1643675 PMid:31306084 PMCid:PMC7012096 Shiff C., 2002, Integrated approach to malaria control, Clinical Microbiology Reviews, 15: 278-293. https://doi.org/10.1128/CMR.15.2.278-293.2002 PMid:11932233 PMCid:PMC118067 Theisen M., Jore M., and Sauerwein R., 2017, Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine, Expert Review of Vaccines, 16: 329-336. https://doi.org/10.1080/14760584.2017.1276833 PMid:28043178
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==